IONS
IonisCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful positive readouts or favorable partner commercialization progress push the stock toward low triple-digit levels as investor risk premium falls.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.6.
What can break
Biotech sector derating that compresses multiples
Momentum
47
Value
41
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $89.24 · Bull $106.24 · Bear $63.74
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-06 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $95.89
Why
Momentum47 · Δ7d +0.4
Value41 · Δ7d +0.1
Sentiment69 · Δ7d +3.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
47
34% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+7.7
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
69
33% active weight
Current posture
7d trendImproving
Δ7d
+3.6
Δ21d
+8.7
Why this grade
Composite grade C. Momentum 46.8 / Value 41.1 / Sentiment 69.1
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$12.46B
Beta
0.29
Shares Out
161.97M
P/E (TTM) · Derived
-32.3
P/S (TTM)
13.15
P/FCF (TTM) · Derived
-41.85
Rev YoY
+17.1%
EPS YoY
+14.9%
Gross Margin
+98.8%
Op Margin
-28.8%
Net Debt
-$1.05B
Current Ratio
2.79
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology